AbbVie’s (ABBV) Overweight Rating Reaffirmed at Cantor Fitzgerald

AbbVie (NYSE:ABBV – Get Free Report)‘s stock had its “overweight” rating reaffirmed by equities researchers at Cantor Fitzgerald in a research report issued on Monday, Benzinga reports. They currently have a $200.00 price target on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 8.91% from the stock’s current price. Other research […]

Leave a Reply

Your email address will not be published.

Previous post Wedbush Boosts Essex Property Trust (NYSE:ESS) Price Target to $301.00
Next post STAG Industrial (NYSE:STAG) PT Raised to $45.00